Soligenix, Inc. announced the appointment of Marco Maria Brughera, DVM, Global Head of the Rare Disease Franchise for Sigma-Tau SpA, to its Board of Directors. Since January 2011, Dr. Brughera has held several positions for the Sigma-Tau Group, including Corporate Research and Development Managing Director of Sigma-Tau SpA, President of Sigma-Tau Research and Board Member of Sigma-Tau Pharmaceuticals. He currently serves on the Board of Gentium SpA.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.332 USD | -7.52% | -16.56% | -56.74% |
23/05 | Sector Update: Health Care Stocks Retreat Late Afternoon | MT |
23/05 | Sector Update: Health Care Stocks Lower Thursday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.74% | 51.13L | |
+11.92% | 12TCr | |
+12.95% | 11TCr | |
-9.14% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-14.52% | 1.63TCr | |
+6.60% | 1.41TCr | |
+30.99% | 1.2TCr |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Soligenix, Inc. Appoints Marco Maria Brughera to the Board of Directors